Third quarter 2025 earnings presentation November 6, 2025 Cautionary statement regarding forward-looking statements This presentation includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be iden ...

Core Insights - Definitive Healthcare reported third quarter results that met or exceeded the high end of their guidance, with Adjusted EBITDA surpassing expectations by $2 million [3] - The company is focused on operational initiatives and investments to enhance performance over time, showing improvements in new customer acquisition and retention rates [3] Financial Highlights - Revenue for Q3 2025 was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024 [6] - Net loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, which included goodwill impairment charges of $228.2 million [6] - Adjusted Net Income was $9.7 million, down from $15.4 million in Q3 2024 [6] - Adjusted EBITDA was $18.9 million, or 32% of revenue, compared to $20.6 million, or 33% of revenue in Q3 2024 [6] Business and Operating Highlights - The company secured new customer wins across all end-markets, providing critical data and insights [4][7] - A large multi-national biopharma selected Definitive Healthcare to enhance their medical affairs operations, demonstrating the value of their Key Opinion Leader datasets [7] - A medical device company transitioned to Definitive Healthcare after their previous provider failed to deliver necessary insights, highlighting the company's competitive advantage [7] Guidance and Outlook - For Q4 2025, revenue is expected to be in the range of $59.0 – $60.0 million, with Adjusted Operating Income anticipated between $13.5 – $14.5 million [8] - Adjusted EBITDA is projected to be in the range of $16.0 – $17.0 million, with an adjusted EBITDA margin of 27 – 29% [8] - Full year 2025 revenue is expected to be between $239.0 – $240.0 million, raising the bottom end of the prior range by $2.0 million [15]

Core Insights - Definitive Healthcare Corp. will report its financial results for Q3 2025 on November 6, 2025, after market close [1] - A conference call and webcast will be held at 5:00 PM (ET) to discuss the financial results [1] Company Overview - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence [3] - The company provides SaaS products and solutions to help clients identify market opportunities and achieve commercial success in the healthcare sector [3]

Core Insights - Definitive Healthcare Corp. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference [1] - The presentation is scheduled for September 9, 2025, at 9:15 a.m. Eastern Time, with a live webcast available [2] Company Overview - Definitive Healthcare specializes in transforming data, analytics, and expertise into healthcare commercial intelligence [3] - The company aims to assist clients in identifying markets, opportunities, and key individuals to influence the future of the healthcare industry [3]

Q2 2025 Performance - Total revenue decreased by 5% year-over-year, from $63.7 million to $60.8 million[16] - Adjusted Gross Profit decreased by 6% year-over-year, from $53.1 million to $50.0 million, with Adjusted Gross Profit margin contracting by 110 bps to 82%[16] - Adjusted EBITDA decreased by 11% year-over-year, from $20.9 million to $18.7 million, with Adjusted EBITDA margin contracting by 210 bps to 31%[16,18] - Unlevered Free Cash Flow (uFCF) decreased by 47% year-over-year, from $21.5 million to $11.5 million[20] Revenue Mix - Subscription revenue mix was 96%, with a 6% year-over-year decline[17] - Professional Services revenue mix was 4%, with a 46% year-over-year growth[17] Cash Flow and Balance Sheet - Cash, cash equivalents & short-term investments decreased by 38% year-over-year, from $296.5 million to $184.2 million[20] - Total debt outstanding decreased by 32% year-over-year, from $250.9 million to $170.6 million[20] - Total remaining performance obligations increased by 1% year-over-year, from $257.6 million to $261.4 million[20] Guidance - Q3 2025 Revenue is expected to be between $59.0 million and $60.0 million, a decrease of 6%-4% year-over-year[24] - Full Year 2025 Revenue is expected to be between $237.0 million and $240.0 million, a decrease of 6%-5% year-over-year[24]

Core Viewpoint - Definitive Healthcare Corp. will report its financial results for the second quarter of 2025 on August 7, 2025, after market close, and will host a conference call to discuss these results [1]. Group 1 - The financial results will cover the period ended June 30, 2025 [1]. - A conference call and webcast will take place at 5:00 PM (ET) / 2:00 PM (PT) on the same day [1]. - The event will be accessible via a live audio webcast on the company's Investor Relations website [2]. Group 2 - A live dial-in option will be available for participants, with domestic and international numbers provided [2]. - A replay of the conference call will be available until September 6, 2025, with specific access numbers and a passcode [2]. Group 3 - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets and opportunities [3]. - The company offers SaaS products and solutions designed to facilitate commercial success in the healthcare market [3].

Q1 2025 Performance - Total revenue decreased by 7% year-over-year to $59.2 million[16] - Adjusted EBITDA declined by 27% year-over-year, reaching $14.7 million[18] - Adjusted EBITDA margin contracted by 670 basis points year-over-year to 25%[18] - Unlevered Free Cash Flow (uFCF) was $22.9 million, a 19% decrease year-over-year[21] - Cash, cash equivalents, and short-term investments totaled $200.7 million, a 32% decrease year-over-year[21] Revenue Mix - Subscription revenue, constituting 97% of the total, experienced a 7% year-over-year decline[17] - Professional Services revenue, accounting for 3% of the total, grew by 9% year-over-year[17] Q2 and FY 2025 Guidance - The company projects Q2 2025 revenue to be between $58.5 million and $60.0 million, representing a year-over-year decrease of 8% to 6%[25] - The company anticipates full-year 2025 revenue to be between $234.0 million and $240.0 million, a year-over-year decrease of 7% to 5%[25] - The company expects full-year 2025 Adjusted EBITDA to be between $61.0 million and $65.0 million, representing 26% to 28% of revenue[25] Shareholder Statistics - Sponsor ownership (as-if converted) is 77,778,491 shares, representing 52.3% of total ownership[30] - Management, Directors & employees ownership is 25,424,644 shares, representing 17.1% of total ownership[30] - Float is 45,438,239 shares, representing 30.6% of total ownership[30]

Core Insights - Definitive Healthcare Corp. reported first quarter results exceeding guidance for both revenue and earnings, driven by strong new customer acquisition and operational efficiency [3][4][6] - The company anticipates revenue for the second quarter of 2025 to be between $58.5 million and $60.0 million, with adjusted operating income expected to be between $12.0 million and $13.0 million [7][8] - For the full year 2025, revenue is projected to be in the range of $234.0 million to $240.0 million, with adjusted net income expected to be between $30.0 million and $34.0 million [13] Financial Performance - Revenue for Q1 2025 was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024 [6] - The net loss for the quarter was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024 [6] - Adjusted net income was $7.0 million, down from $13.0 million in Q1 2024, while adjusted EBITDA was $14.7 million, or 25% of revenue, compared to $20.0 million, or 32% of revenue in Q1 2024 [6][31] Customer Acquisition and Business Development - The company secured several new customer wins in Q1 2025, including a California-based medical device company and a regional health system in the Southern US, highlighting the effectiveness of its data and insights [7] - Definitive Healthcare is expanding its focus on digital marketing activation partnerships, having signed two leading healthcare advertising agencies [7] Cash Flow and Operational Efficiency - Cash flow from operations was $26.1 million in the quarter, with unlevered free cash flow at $22.9 million [6] - The company continues to focus on operational efficiency despite rising macroeconomic uncertainty, maintaining a positive outlook for meeting full-year financial targets [3][4]

Financial Results Announcement - Definitive Healthcare Corp. will report its financial results for the first quarter ended March 31, 2025, on May 8, 2025, after market close [1] - A conference call and webcast will be held at 5:00 PM (ET) / 2:00 PM (PT) to discuss the financial results [1] Webcast and Replay Information - A live audio webcast of the event will be available on Definitive Healthcare's Investor Relations website [2] - A replay of the conference call will be available through June 7, 2025, with specific dial-in numbers and a passcode provided for access [2] Company Overview - Definitive Healthcare aims to transform data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets and opportunities [3] - The company's SaaS products and solutions are designed to create new paths to commercial success in the healthcare market [3]

Group 1 - Definitive Healthcare announced the hiring of two senior leaders, Kate Hastings as Chief Customer Officer and Benjamin Graboske as EVP, Technology, Engineering and Chief Data Officer [1] - The Human Capital Management and Compensation Committee granted inducement awards consisting of 172,414 time-based restricted stock units (RSUs) to Hastings and 1,018,330 time-based RSUs to Graboske, effective March 3, 2025 [1] - The awards were individually negotiated and granted as an inducement material to the commencement of employment in accordance with Nasdaq Listing Rule 5635(c)(4) [1] Group 2 - Hastings' RSUs will vest 25% on February 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [2] - Graboske's RSUs will vest 25% on April 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following three years [3] Group 3 - Definitive Healthcare focuses on transforming data, analytics, and expertise into healthcare commercial intelligence, helping clients identify markets, opportunities, and key personnel [4]